News | March 16, 2012

Cell>Point, FDA Agree on Phase 3 Trial of Technetium-99m Lung Cancer Imaging Agent

March 15, 2012 - Cell>Point announced that it has received a letter from the U.S. Food and Drug Administration (FDA) indicating agreement on a Special Protocol Assessment (SPA) for Cell>Point’s Phase 3 pivotal clinical study of technetium-99m-EC-G in lung cancer.

The Phase 3 study will assess use of Cell>Point’s molecular imaging product candidate, technetium-99m-EC-G (EthylenediCysteine-n-acetyl-Glucosamine), in the diagnosis and staging of lung cancer.

Study patients receive technetium-99m-EC-G (99mTc-EC-G) intravenously, and a picture, or image, of the cancer area is taken using a Single Photon Emission Computed Tomography (SPECT) camera, commonly referred to as a gamma camera.

“We are extremely pleased to receive agreement from the FDA for this Special Protocol Assessment since it provides us confidence that our study design and statistical analysis plan have the potential to provide results that lead to product approval,” said David Rollo, M.D., Ph.D., president of Cell>Point.

Patients in the study will receive a SPECT scan with 99mTc-EC-G, and a PET scan (Positron Emission Tomography) with fluorine-18 FluoroDeoxyGlucose (18F-FDG). Results will then be independently evaluated, scored and compared for accuracy in diagnosing the presence and location of primary as well as metastatic lesions.

About Special Protocol Assessments

A Special Protocol Assessment is a binding declaration between the trial sponsor and the FDA indicating that the Phase 3 clinical study design, endpoints and statistical analyses are acceptable to support regulatory approval of the product. Final marketing approval depends on study results and an evaluation of benefit/risk profile.

About Technetium-99m-EC-G

Technetium-99m-EC-G is a cancer and cardiovascular diagnostic imaging agent developed for use with SPECT cameras, which are widely available throughout the world. In cancer, Phase 2 clinical trial results showed 100 percent concordance between 99mTc-EC-G and 18F-FDG in non-small cell lung cancer lesion

location, size and confidence that lesions represented cancer. For cardiology, Cell>Point is preparing to start a Phase 2 clinical study to evaluate technetium-99m-EC-G in diagnosing patients with Coronary Artery Disease (CAD). One of the Phase 2 objectives is to compare results of giving technetium-99m-EC-G to patients “at rest” to results of a traditional Myocardial Perfusion Imaging (MPI) “stress and rest” study. (The EC-G rest-only study takes 30 to 45 minutes, whereas a traditional MPI study takes 5 to 7 hours.) Results from the Phase 1b CAD study were very encouraging.

For Technetium-99m-EC-G, the company has completed a Brazil license and a select-country Asia Pacific license.

For more information: www.cellpointweb.com

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Minimally Invasive Treatment Provides Relief from Back Pain

Lumbar spine MRI showing disc herniation and nerve root at baseline and one month after treatment

News | Interventional Radiology | January 11, 2018
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
CT Shows Enlarged Aortas in Former Pro Football Players

3-D rendering from a cardiac CT dataset demonstrating mild dilation of the ascending aorta.

News | Computed Tomography (CT) | January 11, 2018
Former National Football League (NFL) players are more likely to have enlarged aortas, a condition that may put them at...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
RSNA 2017 technical exhibits, expo floor, showing new radiology technology advances.
Feature | RSNA 2017 | January 11, 2018
January 11, 2018 — Here is a list of some of the key clinical study presentations, articles on trends and videos from
Hip Steroid Injections Associated with Bone Changes

58-year-old woman with left hip pain. X-ray from one month prior to the steroid/anesthetic injection demonstrates moderate joint space narrowing (arrows) and bony proliferation (arrowheads).

News | Orthopedic Imaging | January 11, 2018
January 11, 2018 – Osteoarthritis patients who received a steroid injection in the hip had a significantly greater in
Overlay Init